Remote Cardiac Monitoring Market Size to Reach USD 16.04 Billion by 2035 at a CAGR of 11.05% – SNS Insider

The U.S. remote cardiac monitoring market is projected to reach $5.02 billion by 2035, while the European market is forecast to reach $4.08 billion. Growth is expected to be driven by AI-enabled arrhythmia detection, CPT reimbursement support, and the shift of cardiac care toward home-based monitoring.

Analysis

This is a low-quality signal for public equities: a long-dated market-size forecast does not establish near-term revenue conversion, and the addressable market is fragmented across device makers, monitoring-service vendors, software platforms, and provider workflows. The investable variable is not AI detection accuracy alone; it is whether reimbursement rates remain adequate after technician, cloud, and sales-force costs. Incremental adoption could therefore favor scaled incumbents with installed cardiology channels rather than pure-play AI vendors.

Near-term beneficiaries from greater ambulatory monitoring intensity are likely iRhythm (IRTC) and, indirectly, Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX), although the latter three have limited earnings sensitivity. IRTC has the clearest operating leverage if monitor volumes rise faster than customer-acquisition and review-labor costs, but it also carries the highest reimbursement and execution risk. Philips (PHG) is a more indirect beneficiary through connected-care infrastructure, but its investment case remains dominated by remediation and supply-chain execution rather than cardiac monitoring.

The contrarian issue is reimbursement-driven commoditization: as AI reduces review time and lowers barriers to entry, payors may eventually recapture savings through lower reimbursement rather than allowing device vendors to retain the margin. Over the next 6-18 months, a durable re-rating requires evidence that AI improves gross margin and clinical yield simultaneously; growth in enrolled patients without a falling cost per report would be a warning sign. The key falsifiers are unfavorable CMS rulemaking, commercial-payor prior-authorization tightening, or IRTC guidance showing monitoring-volume growth below operating-expense growth.

Key Decisions for Investors

• No immediate sector-wide trade: treat the forecast as an alert, not a catalyst. Reassess after CMS reimbursement proposals and the next two quarterly updates from IRTC on revenue per patient, gross margin, and technician labor intensity.
• Build a small 3-6 month watchlist long in IRTC only if it demonstrates accelerating enrollment with stable-to-improving gross margin; target a 15-20% upside on operating-leverage confirmation, with thesis invalidated by a material reimbursement-rate cut or renewed gross-margin deterioration.
• For lower-beta exposure, prefer a basket of ABT, BSX, and MDT over a concentrated remote-monitoring bet; their electrophysiology and cardiac-device franchises provide optionality while limiting dependence on a single CPT-code or payor decision.
• Monitor CMS final rules and commercial-payor policies over the next 6-12 months. A broad reduction in remote-monitoring reimbursement would favor a relative short in IRTC versus long ABT or BSX, as diversified device portfolios can absorb monitoring-margin pressure.